| Literature DB >> 24850137 |
Stavros Polyzoidis1, Keyoumars Ashkan.
Abstract
Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of patients with glioblastoma multiform. Initial Phase I and II trials have demonstrated favorable outcomes with minimal toxicity. In this editorial, the current status and the future challenges of this therapy are discussed.Entities:
Keywords: dendritic cell; glioblastoma multiforme; immunotherapy; overall survival; side-effect
Mesh：
Substances：
Year: 2014 PMID： 24850137 DOI： 10.1586/14737140.2014.921571
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN： 1473-7140 Impact factor: 4.512